Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 739

The DOI matches its Crossref record; 190 of the 190 references it cites were found in a registry or an index.

Targeted therapy for hepatocellular carcinoma

Open access
Huang, Ao, Yang, Xin-Rong, Chung, Wen-Yuan, Dennison, Ashley R., Zhou, Jian·2020·Signal Transduction and Targeted Therapy

Abstract

The last 3 years have seen the emergence of promising targeted therapies for the treatment of hepatocellular carcinoma (HCC). Sorafenib has been the mainstay of treatment for a decade and newer modalities were ineffective and did not confer any increased therapeutic benefit until the introduction of lenvatinib which was approved based on its non-inferiority to sorafenib. The subsequent success of regorafenib in HCC patients who progress on sorafenib treatment heralded a new era of second-line treatment and was quickly followed by ramucirumab, cabozantinib, and the most influential, immune checkpoint inhibitors (ICIs). Over the same period combination therapies, including anti-angiogenesis agents with ICIs, dual ICIs and targeted agents in conjunction with surgery or other loco-regional therapies, have been extensively investigated and have shown promise and provided the basis for exciting clinical trials. Work continues to develop additional novel therapeutic agents which could potentially augment the presently available options and understand the underlying mechanisms responsible for drug resistance, with the goal of improving the survival of patients with HCC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41392-020-00264-x

Cites

190 of 190 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 190 references

Cited by

See all 739

Metadata

Authors
Huang, A., Yang, X.-R., Chung, W.-Y., Dennison, A. R., & Zhou, J.
Venue
Signal Transduction and Targeted Therapy
Published
2020-08-11
Volume
5
Issue
1
Pages
146-146
ISSN
2059-3635 (ISSN-L)
OpenAlex
W3048102544
Cited by
739
References
190
FWCI
44.55
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeted therapy for hepatocellular carcinoma. https://app.cochat.ai/papers/10.1038/s41392-020-00264-x
The paper
Huang, A., Yang, X.-R., Chung, W.-Y., Dennison, A. R., & Zhou, J. (2020). Targeted therapy for hepatocellular carcinoma. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-020-00264-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.